(Q37951525)

25 August 2017

title

Developments in virus-like particle-based vaccines for infectious diseases and cancer (English)

1 reference

25 August 2017

Maria Tagliamonte

2

0 references

Luigi Buonaguro

object named as

Luigi Buonaguro

series ordinal

1

0 references

Maria Lina Tornesello

object named as

Maria Lina Tornesello

series ordinal

3

0 references

Franco M Buonaguro

series ordinal

4

object named as

Franco M Buonaguro

1 reference

25 August 2017

language of work or name

1 reference

1 November 2011

1 reference

Expert Review of Vaccines

25 August 2017

published in

1 reference

25 August 2017

volume

10

1 reference

25 August 2017

issue

11

1 reference

25 August 2017

page(s)

1569-1583

1 reference

Wanted, dead or alive: New viral vaccines

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Vaccine-Associated Paralytic Poliomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Human hepatitis B vaccine from recombinant yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Recombinant DNA hepatitis B vaccine containing Pre-S components of the HBV coat protein--a preliminary study on immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

A controlled trial of a human papillomavirus type 16 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Patented cancer vaccines: the promising leads

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Recent advances in cancer vaccines: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Principles of vaccine design-Lessons from nature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Human papillomavirus-like particles mediate functional delivery of plasmid DNA to antigen presenting cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

In vitro gene transfer using human papillomavirus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Virus-like particle vaccines and adjuvants: the HPV paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

A "NEW" ANTIGEN IN LEUKEMIA SERA

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Virus-like particles as particulate vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Formation of poliovirus-like particles by recombinant baculoviruses expressing the individual VP0, VP3, and VP1 proteins by comparison to particles derived from the expressed poliovirus polyprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Recombinant RNA phage Q beta capsid particles synthesized and self-assembled in Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Influenza vaccines based on virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

High efficient production of Pr55(gag) virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Chimeric HIV-1 virus-like particles containing gp120 epitopes as a result of a ribosomal frameshift elicit Gag- and SU-specific murine cytotoxic T-lymphocyte activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Native display of complete foreign protein domains on the surface of hepatitis B virus capsids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Chimaeric HIV-1 subtype C Gag molecules with large in-frame C-terminal polypeptide fusions form virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

CD8alpha- CD11b+ dendritic cells present exogenous virus-like particles to CD8+ T cells and subsequently express CD8alpha and CD205 molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Vaccines that facilitate antigen entry into dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Th2 polarization in peripheral blood mononuclear cells from human immunodeficiency virus (HIV)-infected subjects, as activated by HIV virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Yeast-derived human immunodeficiency virus type 1 p55(gag) virus-like particles activate dendritic cells (DCs) and induce perforin expression in Gag-specific CD8(+) T cells by cross-presentation of DCs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Human immunodeficiency virus-like particles activate multiple types of immune cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Nanoparticles target distinct dendritic cell populations according to their size

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Neutralizing antiviral B cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Virus-like particle vaccine activates conventional B2 cells and promotes B cell differentiation to IgG2a producing plasma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Molecular immune signatures of HIV-1 vaccines in human PBMCs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Infectious and whole inactivated simian immunodeficiency viruses interact similarly with primate dendritic cells (DCs): differential intracellular fate of virions in mature and immature DCs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Ebola and Marburg virus-like particles activate human myeloid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Influence of dendritic cells on viral pathogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Activation of the lectin DC-SIGN induces an immature dendritic cell phenotype triggering Rho-GTPase activity required for HIV-1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Hepatitis C Virus Inhibits Cell Surface Expression of HLA-DR, Prevents Dendritic Cell Maturation, and Induces Interleukin-10 Production

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Recognition of viruses by innate immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Incorporation of glycosylphosphatidylinositol-anchored granulocyte- macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Role of Toll-like receptors in costimulating cytotoxic T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Particles associated with Australia antigen in the sera of patients with leukaemia, Down's Syndrome and hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Multiple chemical forms of hepatitis B surface antigen produced in yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Synthesis and assembly of hepatitis B virus surface antigen particles in yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Childhood Cancer Among Alaska Natives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Virus-like particle expression and assembly in plants: hepatitis B and Norwalk viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Low-dose oral immunization with lyophilized tissue of herbicide-resistant lettuce expressing hepatitis B surface antigen for prototype plant-derived vaccine tablet formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

A DNA replicon system for rapid high-level production of virus-like particles in plants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Immunogenicity of peptide fusions to hepatitis B virus core antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

HBV core particles as a carrier for B cell/T cell epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus (HCV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Melanoma vaccine candidates from chimeric hepatitis B core virus-like particles carrying a tumor-associated MAGE-3 epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

A hantavirus nucleocapsid protein segment exposed on hepatitis B virus core particles is highly immunogenic in mice when applied without adjuvants or in the presence of pre-existing anti-core antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Internal core protein cleavage leaves the hepatitis B virus capsid intact and enhances its capacity for surface display of heterologous whole chain proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Development of hepatitis B virus capsids into a whole-chain protein antigen display platform: new particulate Lyme disease vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Translational fusion of chloroplast-expressed human papillomavirus type 16 L1 capsid protein enhances antigen accumulation in transplastomic tobacco.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

HPV6b virus like particles are potent immunogens without adjuvant in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

A protective and broadly cross-neutralizing epitope of human papillomavirus L2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Tomato is a highly effective vehicle for expression and oral immunization with Norwalk virus capsid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Recombinant Norwalk virus-like particles given orally to volunteers: phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Puumala (PUU) hantavirus strain differences and insertion positions in the hepatitis B virus core antigen influence B-cell immunogenicity and protective potential of core-derived particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

A universal influenza A vaccine based on the extracellular domain of the M2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Evaluation of HBs, HBc, and frCP virus-like particles for expression of human papillomavirus 16 E7 oncoprotein epitopes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Recombinant dengue virus type 2 envelope/hepatitis B surface antigen hybrid protein expressed in Pichia pastoris can function as a bivalent immunogen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Natural history of human respiratory syncytial virus inferred from phylogenetic analysis of the attachment (G) glycoprotein with a 60-nucleotide duplication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Determinants of autoantibody induction by conjugated papillomavirus virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

A vaccine against nicotine for smoking cessation: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

M2e-based universal influenza A vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Therapeutic vaccination for future management of HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Development of baculovirus triple and quadruple expression vectors: co-expression of three or four bluetongue virus proteins and the synthesis of bluetongue virus-like particles in insect cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Cloning and nucleotide sequence of the simian rotavirus gene 6 that codes for the major inner capsid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Intrarectal immunization with rotavirus 2/6 virus-like particles induces an antirotavirus immune response localized in the intestinal mucosa and protects against rotavirus infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Mice develop effective but delayed protective immune responses when immunized as neonates either intranasally with nonliving VP6/LT(R192G) or orally with live rhesus rotavirus vaccine candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

HIV-specific humoral and cellular immunity in rabbits vaccinated with recombinant human immunodeficiency virus-like gag-env particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Enhanced mucosal immune responses to HIV virus-like particles containing a membrane-anchored adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Multiple tandem copies of conserved gp41 epitopes incorporated in gag virus-like particles elicit systemic and mucosal antibodies in an optimized heterologous vector delivery regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Constitutive expression of HIV-VLPs in stably transfected insect cell line for efficient delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotaviruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Induction of long-term protective immune responses by influenza H5N1 virus-like particles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Induction of HIV type 1 neutralizing and env-CD4 blocking antibodies by immunization with genetically engineered HIV type 1-like particles containing unprocessed gp160 glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduces their capacity to induce neutralizing antibodies and delineates a conformational neutralizing epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Influenza virus-like particles as an antigen-carrier platform for the ESAT-6 epitope of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Engineering of SV40-based nano-capsules for delivery of heterologous proteins as fusions with the minor capsid proteins VP2/3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

Presentation of functional foreign peptides on the surface of SV40 virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.135

21 January 2018

Identifiers

DOI

10.1586/ERV.11.135

1 reference

25 August 2017

1 reference